[Sucralfate: the agent of choice in the treatment of peptic ulcer?]. 1990

N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib

As many as 72 patients with erosive and ulcerous injuries to the stomach and duodenum were examined for the clinical efficacy of antepsin (sucralfate). Of these patients, 42 were with duodenal ulcer, 10 with gastric ulcer and 20 with erosive gastroduodenitis). Antepsin exerted a beneficial effect on the painful syndrome and on ulcer and erosion healing. The coefficient of the therapeutic efficacy of antepsin in duodenal ulcer patients turned out to be equal to 2.67 that of gastric ulcer to 2.1 and that in patients with gastroduodenitis was 2.6. The drug did not produce any well-defined side effects. In some cases (8.3%), it caused the appearance or enhancement of constipation. Antepsin is indicated not only in ulcer disease but also in duodenogastric reflux, reflux gastritis and reflux esophagitis.

UI MeSH Term Description Entries
D008297 Male Males
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004381 Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM. Curling's Ulcer,Curling Ulcer,Curlings Ulcer,Duodenal Ulcers,Ulcer, Curling,Ulcer, Duodenal,Ulcers, Duodenal
D004382 Duodenitis Inflammation of the DUODENUM section of the small intestine (INTESTINE, SMALL). Erosive duodenitis may cause bleeding in the UPPER GI TRACT and PEPTIC ULCER. Erosive Duodenitis,Duodenitis, Erosive
D005260 Female Females
D005750 Gastric Juice The liquid secretion of the stomach mucosa consisting of hydrochloric acid (GASTRIC ACID); PEPSINOGENS; INTRINSIC FACTOR; GASTRIN; MUCUS; and the bicarbonate ion (BICARBONATES). (From Best & Taylor's Physiological Basis of Medical Practice, 12th ed, p651) Gastric Juices,Juice, Gastric,Juices, Gastric
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D005756 Gastritis Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders. Gastritides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
April 1983, The Practitioner,
N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
August 1991, Klinicheskaia meditsina,
N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
January 1989, Klinicheskaia meditsina,
N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
September 1983, Drug and therapeutics bulletin,
N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
July 1986, Clinical pharmacy,
N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
August 1991, The American journal of medicine,
N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
April 1984, The Medical letter on drugs and therapeutics,
N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
May 1965, Nutrition reviews,
N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
January 1982, Pharmacotherapy,
N E Fedorov, and A A Laktionova, and A V Tkachev, and A A Iakovlev, and L V Soboleva, and V M Grib
January 1982, Clinical pharmacy,
Copied contents to your clipboard!